## Zoltan Vajo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7683444/publications.pdf

Version: 2024-02-01

393982 344852 1,383 44 19 36 citations h-index g-index papers 46 46 46 1601 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccinesâ€"Correlates of Immunogenicity Parameters with Protection. Viruses, 2022, 14, 196.	1.5	1
2	A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients. Viruses, 2021, 13, 500.	1.5	3
3	Licensing the first reduced, 6â€-µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine – A randomized-controlled multicenter trial. Vaccine, 2019, 37, 258-264.	1.7	3
4	Dose sparing and the lack of a dose–response relationship with an influenza vaccine in adult and elderly patients – a randomized, doubleâ€blind clinical trial. British Journal of Clinical Pharmacology, 2017, 83, 1912-1920.	1.1	11
5	Pulseless electrical activity in pulmonary embolism treated with thrombolysis (from the "PEAPETTâ€) Tj ETQq1	1.0.78431 0.7	.4.rgBT /Ove
6	New Oral Anticoagulants in the Treatment of Heparin-Induced Thrombocytopenia. Thrombosis Research, 2015, 135, 607-609.	0.8	44
7	Transforming and Simplifying the Treatment of Pulmonary Embolism: "Safe Dose―Thrombolysis Plus New Oral Anticoagulants. Lung, 2015, 193, 369-374.	1.4	14
8	Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination. Archives of Virology, 2013, 158, 2577-2581.	0.9	3
9	A Reduced-Dose Seasonal Trivalent Influenza Vaccine Is Safe and Immunogenic in Adult and Elderly Patients in a Randomized Controlled Trial. Vaccine Journal, 2012, 19, 313-318.	3.2	6
10	The seasonal influenza vaccine Agriflu (sup) $\hat{A}^{\otimes}$ (sup). Expert Review of Vaccines, 2011, 10, 1513-1517.	2.0	3
11	A Single-Dose Influenza A (H5N1) Vaccine Safe and Immunogenic in Adult and Elderly Patients: an Approach to Pandemic Vaccine Development. Journal of Virology, 2010, 84, 1237-1242.	1.5	22
12	Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial. Lancet, The, 2010, 375, 49-55.	6.3	147
13	Cross-Reactive Immunity to Clade 2 Strains of Influenza Virus A Subtype H5N1 Induced in Adults and Elderly Patients by Fluval, a Prototype Pandemic Influenza Virus Vaccine Derived by Reverse Genetics, Formulated with a Phosphate Adjuvant, and Directed to Clade 1 Strains. Vaccine Journal, 2009, 16, 437-443.	3.2	19
14	Cardiovascular risk status and primary prevention in postmenonausal women; the MENOCARD study	1.0	7
15	Influenza A (H5N1) pandemic prototype vaccine Fluval (sup) $\hat{A}^{\otimes}$ (sup). Expert Review of Vaccines, 2009, 8, 619-624.	2.0	5
16	Cutaneous granuloma and uveitis caused by a tattoo. Wiener Klinische Wochenschrift, 2008, 120, 18-18.	1.0	15
17	Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval – a useful approach to pandemic vaccine development even in less well developed countries?. Influenza and Other Respiratory Viruses, 2008, 2, 221-228.	1.5	14
18	Safety and Immunogenicity of a Prepandemic Influenza A (H5N1) Vaccine in Children. Pediatric Infectious Disease Journal, 2008, 27, 1052-1056.	1.1	24

#	Article	IF	Citations
19	Inactivated Whole Virus Influenza A (H5N1) Vaccine1. Emerging Infectious Diseases, 2007, 13, 807-808.	2.0	32
20	Echocardiographic findings in patients with Williams-Beuren syndrome. Wiener Klinische Wochenschrift, 2006, 118, 538-542.	1.0	19
21	Uterine leiomyosarcoma with osteoclast like giant cells and long standing systemic symptoms. Gynecologic Oncology, 2006, 102, 403-405.	0.6	22
22	The role of dental evaluation and cephalometric analysis in the diagnosis of Williams–Beuren syndrome. Wiener Klinische Wochenschrift, 2005, 117, 226-228.	1.0	9
23	Estrogen replacement therapy reverses changes in intramural coronary resistance arteries caused by female sex hormone depletion. Cardiovascular Research, 2004, 61, 317-324.	1.8	21
24	Effect of simvastatin on endothelial function in cardiac syndrome X patients. American Journal of Cardiology, 2004, 94, 652-655.	0.7	67
25	Managing lipid disorders: Further evaluation of the VA-hit. Current Diabetes Reports, 2003, 3, 245-247.	1.7	0
26	Sex hormone replacement therapy reverses altered venous contractility in rats after pharmacological ovariectomy. Menopause, 2002, 9, 122-126.	0.8	10
27	Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis, 2002, 160, 495-501.	0.4	35
28	Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs. Endocrine Reviews, 2001, 22, 706-717.	8.9	153
29	Sex hormone replacement therapy reverses decreased venous distensibility in pharmacologically ovariectomized rats. Menopause, 2001, 8, 204-209.	0.8	10
30	Insulin and Analogue Effects on Protein Degradation in Different Cell Types. Journal of Biological Chemistry, 2001, 276, 11552-11558.	1.6	23
31	Hormone Replacement Reduces Elevated In Vivo Venous Tone in Hypertensive Ovariectomized Rats. Journal of the Society for Gynecologic Investigation, 2001, 8, 98-103.	1.9	4
32	Hormone Replacement Therapy Reduces Mean 24-Hour Blood Pressure and Its Variability in Postmenopausal Women with Treated Hypertension. Menopause, 2000, 7, 31-35.	0.8	47
33	Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1017-1021.	1.1	70
34	For debate: defective mitochondria, free radicals, cell death, aging-reality or myth-ochondria?. Mechanisms of Ageing and Development, 2000, 114, 201-206.	2,2	31
35	Coenzyme Q Deficiency in Two Unrelated Patients—Molecular Studies. Fetal and Pediatric Pathology, 2000, 19, 69-72.	0.3	1
36	Postmenopausal Hormone Replacement Therapy and Cardiovascular Mortality in Central-Eastern Europe. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2000, 55, M160-M162.	1.7	6

#	Article	IF	CITATIONS
37	Alterations of Venous Drug Reactivity in Humans: Acquired and Genetic Factors. Angiology, 2000, 51, 361-366.	0.8	o
38	The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans*. Endocrine Reviews, 2000, 21, 23-39.	8.9	262
39	Conservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for aging. Mammalian Genome, 1999, 10, 1000-1004.	1.0	76
40	Paradoxically Enhanced Bradykinin-Induced Venodilation in Young, Healthy, Short-Term Smokers. Journal of Cardiovascular Pharmacology, 1999, 34, 316-319.	0.8	7
41	Picture of the Month. JAMA Pediatrics, 1998, 152, 1149; discussion 1150.	3.6	3
42	Endobronchial Thrombolysis With Streptokinase for Airway Obstruction Due to Blood Clots. Mayo Clinic Proceedings, 1996, 71, 595-596.	1.4	23
43	Prostacyclin and thromboxane production of rat and cat arterial tissue is altered independently by several vasoactive substances. Prostaglandins, 1996, 52, 221-235.	1.2	5
44	Impaired β2-adrenergic agonist–induced venodilation in Indians of Asian origin*. Clinical Pharmacology and Therapeutics, 1996, 59, 569-576.	2.3	10